1. Scrip
  2. >>Business

Spotlight On TissueGene’s Upcoming Korea IPO

 
• By Jung Won Shin

Regenerative drug company TissueGene’s proposed IPO in South Korea is drawing keen interest, coming close on the heels of the recent approval of its novel osteoarthritis drug in the country. Success of the IPO will be crucial for the company to proceed with a Phase III US study of the drug.

Money Wave

TissueGene Inc. is gearing to launch an initial public offering in South Korea to finance a Phase III US clinical trial of Invossa, its first-in-class cell and gene therapy drug. Invossa was approved by South Korean authorities in July making it the country's first gene therapy and the world’s first allogeneic cell mediated gene therapy for degenerative osteoarthritis.

The US-based TissueGene, which is part of South Korea’s Kolon Group, aims to raise KRW120bn ($105.7m) to KRW202.5bn from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total deal value of GLP-1-associated assets globally this year is already double that of the previous two years combined, with China-originated assets accounting for a substantial majority.

Finance Watch: CSL Restructuring Brings 15% Workforce Reduction, Vaccines Group Spinout

 
• By Mandy Jackson

Restructuring Edition: CSL Group will spin out CSL Seqirus as a standalone vaccines business as the parent company slims down. Some struggling companies are turning to investing in cryptocurrencies to create shareholder value.

Discontinuations For Viking’s Oral Obesity Drug VK2735 Scare Investors

 
• By Joseph Haas

Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.

More from Scrip

Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection

 
• By Alaric DeArment

PTC said it got a complete response letter for the Friedreich’s ataxia drug, with the agency asking for an additional clinical trial.

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 
• By Andrew McConaghie

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Egetis Eyes Swift US Submission For Emcitate

 
• By Kevin Grogan

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.